Market Research Logo

China Human Vaccine Industry Report, 2018-2022

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination.

The lot release volume of human vaccines has remained at around 650 million doses over the past three years. China Food and Drug Administration (CFDA) approved the launch of 9-valent human papillomavirus vaccine (saccharomyces cerevisiae) and oral 5-valent reassortant rotavirus attenuated live vaccine (Vero cell) in the first half of 2018. The National Institutes for Food and Drug Control, Hubei Institute for Food and Drug Control, and Shanghai Institute for Food and Drug Control approved supply of 434.1 million doses (44 kinds of vaccines) to the market from January to September 2018.

With annual capacity of over one billion doses, more than forty vaccine manufacturers in China are capable of producing 63 kinds of vaccines for prevention of 34 sorts of infectious diseases. Among them, Chengdu Institute of Biological Products, Shanghai Institute of Biological Products, Lanzhou Institute of Biological Products, Wuhan Institute of Biological Products, Changchun Institute of Biological Products, Beijing Bio-Institute Biological Products, Changchun KEYGEN Biological Products, and Beijing Tiantan Biological Products (Beijing Tiantan Biological Products has no vaccine business after completion of asset restructuring in May 2017) under China National Biotech Group Co., Ltd. occupy half of the Chinese vaccine market. The subsidiaries under China National Biotech Group Co., Ltd. recorded lot release volume of 349.147 million doses in 2017 and 198.261 million doses in the first nine months of 2018, making up 53.1% and 45.7% of the country’s total amount, respectively.

In recent years, Chinese vaccine companies have spared no efforts in research and development to sharpen competitiveness. As yet, not a Chinese enterprise can produce HPV vaccines and 13-valent pneumonia vaccines, but local companies including Walvax Biotechnology and Shenzhen Kangtai Biological Products are developing such vaccines which are expected to be available soon.

With the implementation of two-child policy, the aging of population and the launch of new-type vaccines, China’s human vaccine industry will grow steadily in future, with the expected market size of RMB35.2 billion by 2022. Meanwhile, vaccine companies with richer capital and stronger R&D strength will give play to technological superiorities and scale effect, and raise their market share through capital operation and other means. In this sense, China’s vaccine industry tends to feature higher and higher concentration.

China Human Vaccine Industry Report, 2018-2022 highlights the following:
China’s human vaccine industry (operating environment, status quo, market demand, distribution channels, market size, import and export, and competitive landscape);
Chinese human vaccine market segments (market demand, lot release volume and competitive landscape);
22 human vaccine companies (operation, R&D and investment, development strategy, etc.) .

Please Note: PDF E-mail from Publisher purchase option allows up to 10 users and does not allow printing or editing. This functionality will require a Global Site License.


1. Overview of Vaccine Industry
1.1 Definition & Classification
1.2 Industry Chain
2. China Human Vaccine Industry
2.1 Operating Environment
2.1.1 International Market
2.1.2 Policy Environment
2.1.3 Biopharmaceutical Market
2.2 Status Quo
2.3 Market Demand
2.4 Circulation Channels
2.5 Market Size
2.6 Import & Export
2.6.1 Import
2.6.2 Export
2.6.3 Average Price
2.7 Competition Pattern
3. Human Vaccine Market Segments in China
3.1 Hepatitis B Vaccine
3.1.1 Demand
3.1.2 Lot Release Volume
3.1.3 Competition Pattern
3.2 Meningococcal Vaccine
3.2.1 Demand
3.2.2 Lot Release Volume
3.2.3 Competition Pattern
3.3 Hepatitis A Vaccine
3.3.1 Demand
3.3.2 Lot Release Volume
3.3.3 Competition Pattern
3.4 Influenza Vaccine
3.4.1 Demand
3.4.2 Lot Release Volume
3.4.3 Competition Pattern
3.5 Hib Vaccine
3.5.1 Demand
3.5.2 Lot Release Volume
3.5.3 Competition Pattern
3.6 Human Rabies Vaccine
3.6.1 Demand
3.6.2 Lot Release Volume
3.6.3 Competition Pattern
3.7 Varicella Vaccine
3.7.1 Demand
3.7.2 Lot Release Volume
3.7.3 Competition Pattern
3.8 Pneumococcal Vaccines
3.8.1 Demand
3.8.2 Lot Release Volume
3.8.3 Competition Pattern
3.9 DTP Vaccine
3.9.1 Demand
3.9.2 Lot Release Volume
3.9.3 Competition Pattern
3.10 Poliomyelitis Vaccine
3.10.1 Demand
3.10.2 Lot Release Volume
3.10.3 Competition Pattern
3.11 Hepatitis E Vaccine
3.11.1 Demand
3.11.2 Lot Release Volume
3.11.3 Competition Pattern
4. Major Human Vaccine Manufacturers in China
4.1 China National Biotech Group
4.1.1 Profile
4.1.2 National Vaccine and Serum Institute
4.1.3 Chengdu Institute of Biological Products Co., Ltd.
4.1.4 Shanghai Institute of Biological Products Co., Ltd.
4.1.5 Wuhan Institute of Biological Products Co., Ltd.
4.1.6 Lanzhou Institute of Biological Products Co., Ltd.
4.1.7 Changchun Institute of Biological Products Co., Ltd.
4.2 Beijing Tiantan Biological Products Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D
4.2.6 Vaccine Business
4.3 Hualan Biological Engineering Inc.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 R&D
4.3.5 Vaccine Business
4.3.6 Development Strategy
4.4 Chongqing Zhifei Biological Products Co., Ltd.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 R&D
4.4.6 Development Dynamics
4.4.7 Development Strategy
4.5 Walvax Biotechnology Co, Ltd.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 R&D
4.5.6 Vaccine Business
4.5.7 Development Trend
4.6 Liaoning Cheng Da Co., Ltd.
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 Major Customers
4.6.6 R&D
4.6.7 Development Strategy
4.7 Shenzhen Kangtai Biological Products Co., Ltd.
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 R&D
4.7.6 Development Strategy
4.8 Changsheng Bio-Technology Co., Ltd.
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 R&D
4.8.5 Development Dynamics
4.9 Olymvax Biopharmaceuticals Inc.
4.9.1 Profile
4.9.2 Operation
4.9.3 R&D
4.10 Sinovac Biotech Ltd.
4.10.1 Profile
4.10.2 Operation
4.10.3 Revenue Structure
4.10.4 Sinovac Biotech (Beijing)
4.11 Changchun BCHT Biotechnology Co. Ltd.
4.11.1 Profile
4.11.2 Operation
4.11.3 Development Dynamics
4.12 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
4.12.1 Profile
4.12.2 Operation
4.13 Dalian Hissen Bio-Pharm Co., Ltd.
4.13.1 Profile
4.13.2 Vaccine Business
4.14 NCPC GeneTech Biotechnology Development Co., Ltd.
4.14.1 Profile
4.14.2 Operation
4.15 Dalian Aleph Biomedical Co., Ltd.
4.15.1 Profile
4.15.2 Vaccine Business
4.16 Beijing Minhai Biotechnology Co., Ltd.
4.16.1 Profile
4.16.2 Operation
4.17 Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
4.17.1 Profile
4.17.2 Operation
4.18 Other Enterprises
4.18.1 Xiamen Innovax Biotech Co., Ltd.
4.18.2 Convac Biotechnology Co., Ltd.
4.18.3 Chengdu Kanghua Biological Products Co.,Ltd.
4.18.4 Guangzhou Nuocheng Biological Products
4.18.5 CanSino Biologics Inc.
5 Summary and Forecast
5.1 Summary
5.2 Development Trends
5.2.1 Human Vaccine Industry is Increasingly Concentrated
5.2.2 Two-child Policy is in Favor of Human Vaccine Industry Growth
5.2.3 Faster Aging of Population Boosts Human Vaccine Industry
5.2.4 Human Papillomavirus (HPV) Vaccine Market is Promising
5.2.5 Homemade 13-valent Pneumococcal Conjugate Vaccine is Likely to be Launched
5.2.6 Local Companies Invest More Heavily in Research and Development of Vaccine Products Which are Becoming More Various

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report